DACH family-office research should separate Germany, Austria and Switzerland, company entry stage and the actual capital vehicle. A Vienna family office supporting early B2B products, a Swiss mental-health venture arm and a German B2B software investor are not three versions of the same funding offer. This guide compares 15 family-capital routes, including clearly labeled international specialists where the published mandate supports the region.
Match the DACH company, stage and family-capital route
- Record the company's real German, Austrian or Swiss connection and present evidence milestone.
- Check whether direct company investment is currently documented, rather than only fund commitments.
- Separate pre-seed, seed, Series A and later company strategies. A family office is not a funding stage.
- Review regional scope and sector exclusions before asking for an introduction.
Compare 15 family-capital startup investor routes
Sources reviewed November 13, 2026. This is a selected research directory, not a ranking. Company entry stages, fund allocation and later-stage strategies are kept separate. On mobile, scroll the comparison sideways.
| Investor | Product focus | Stage or route | Geographic filter |
|---|---|---|---|
| Reimann Investors | B2B software, AI and fintech | Seed and Series A; validated customer value | Germany, Austria and Switzerland |
| Mutschler Ventures | Fintech, digital health, software, cleantech and mobility | Seed follow-on; initial revenue and validation | DACH-focused with broader portfolio experience |
| Wille Finance | ICT and life sciences | Venture: Series A and B; buyout is separate | European venture strategy; DACH buyout scope is distinct |
| Winterberg Group | Industrial technology and emerging-middle-class themes | Seed and Round A; mature buyouts are separate | Europe, US and South Africa under early-growth criteria |
| Armada Investment | Technology and scientific company building | All venture stages; company-specific | Europe and the United States |
| Halfmeyer Ventures | Software-led health tech, AI, commerce and automation | Pre-seed and seed; product, prototype or validated problem | Europe and beyond; no Berlin-residence requirement |
| Kodori | Kodori Ventures focuses on mental health | Early-stage venture arm; precise entry policy to confirm | Zug-based; confirm company-market scope |
| RM Beteiligungsverwaltung | Early-stage company investment; sector policy to confirm | Early-stage companies; detailed criteria not published | German-based; confirm the company's geographic fit |
| BLN Capital | Technology and gaming | Pre-seed and seed for direct venture strategy | Europe and the United States |
| Stinson | Sustainable company development across industries | Startups and established companies; entry stage not specified | Germany-based with an international network |
| ROI Ventures | Technology-driven B2B startups and consumer brands | Early-stage B2B; consumer angel and pre-seed; separate growth route | Europe; Austrian base |
| SABER | Multi-sector direct startup investment | Private growth companies; precise initial round to confirm | Europe, the US and Israel; Vienna-based |
| Apeiron Investment Group | Transformative technology and human health | Incubation to growth and public holdings; strategy-specific | Global; primary US focus; European teams |
| Adeline Arts & Science | Frontier technology, AI, science, climate and health | Pre-seed through Series A | UK and European sourcing, including DACH; global outlook |
| CPT Capital | Alternative protein, food technology and enabling infrastructure | Pre-seed and seed, with follow-on investing | Global, including Europe and Israel |
Read provider criteria and approach routes
1. Reimann Investors
Family-office-backed venture platform. The published DACH mandate is specific enough to screen a company before outreach. Show validated customer value and the route to a larger market. Do not transfer an affiliated asset-management offering or a historical fund's stage range into the startup pitch.
Founder route: Pitch to us route. Official criteria.
2. Mutschler Ventures
Single-family-office venture arm. Mutschler asks for initial revenue and validation and positions itself as a seed follow-on investor. A pre-revenue idea-only pitch is therefore a different case. Its current exclusions include biotech and medtech, which must not be relabeled as digital-health eligibility.
Founder route: Published direct inbox; warm introductions welcomed. Official criteria.
3. Wille Finance
Single-family office. Wille places venture and buyout criteria alongside one another. Use the European Series A-and-B company strategy when evaluating a startup, not the buyout column. The team invites cases that fit its profile, making the actual technology and development milestone central to the approach.
Founder route: Private equity team contact on the official page. Official criteria.
4. Winterberg Group
Multi-family investment office. Its early-growth strategy and mature industrial buyout strategy answer different funding jobs. Select the seed or Round A route and explain the growth evidence, team and market. A European office alone does not mean a company qualifies for both strategies.
Founder route: Official Contact Form. Official criteria.
5. Armada Investment
Founder-family proprietary investment office. Armada states that it invests its own capital and backs venture founders in Europe and the US across stages. The founder-capital structure can be relevant to an unusual development path, but the company still needs a specific technological and commercial case.
Founder route: Published corporate contact information. Official criteria.
6. Halfmeyer Ventures
Family office and venture studio. A software-led company can qualify before revenue when it has relevant proof. A hardware-only or idea-only proposition is not equivalent. Explain whether operator involvement would help, and distinguish a direct investment request from incubation or paid advisory work.
Founder route: Public cold-pitch form. Official criteria · Supporting official evidence.
7. Kodori
Swiss-family-office-backed private investment company. Kodori describes a specific mental-health venture focus within a broader family-backed investment company. Identify that strategy first. An old investment elsewhere in the parent portfolio is not proof that every cybersecurity, consumer or medical startup is currently in scope.
Founder route: Official contact information. Official criteria.
8. RM Beteiligungsverwaltung
Entrepreneur's private investment company. Roland Metzger's private investment company identifies early-stage companies as its present emphasis. That is useful as an initial stage screen, but not a published ticket or sector commitment. Approach with the company's concrete proof and one question about current fit.
Founder route: Official Contact page. Official criteria.
9. BLN Capital
Founder-owned private investment office. BLN separates direct early-stage investments from fund commitments. For a company raise, use the venture strategy rather than an LP-facing relationship. Its operator background is relevant to product and growth discussions, but it does not remove the need for an actual market and stage match.
Founder route: Official Contact us route. Official criteria.
10. Stinson
Single-family office. Stinson's current strategy expressly includes startups and established companies. Treat that as a reason to research the team, not an automatic pre-seed qualification. Explain the business model, development potential and operating work where a hands-on family partner could contribute.
Founder route: Official contact email and Contact section. Official criteria.
11. ROI Ventures
Family office. ROI publishes different propositions for early technology companies, retail consumer brands and later growth or secondaries. A B2B founder should not reuse a consumer-brand ticket as a blanket term. Make the product, buyer and relevant investment route explicit.
Founder route: Get In Touch page. Official criteria.
12. SABER
Single-family office. SABER's official company profile distinguishes direct startups from fund allocation and names a growth-company preference. That is not evidence of idea-stage eligibility. No working public deck form was verified, so treat the company profile as a research route, not an open funding application.
Founder route: Official company profile; no public deck form verified. Official company profile.
13. Apeiron Investment Group
Founder-owned proprietary investment platform. Apeiron separates proprietary company investing from anchor LP positions and GP stakes. A startup should identify the direct-company thesis and actual investing entity. Its global scope does not mean every European company or sector fits the present priorities.
Founder route: Official contact form. Official criteria.
14. Adeline Arts & Science
Family office. Adeline's early-stage strategy combines science and technology with a long-term view. Its team describes UK and DACH experience. Explain the technical leverage and next proof point, and use the startup pitch route rather than a scientific-research or arts request.
Founder route: Pitch us form on the official site. Official criteria.
15. CPT Capital
Private-family-office venture arm. CPT's worldwide mandate and early entry stage make it a specific route for alternative-protein companies, including European teams. It is not a general climate or consumer-food investor. Match the technological mechanism and show why it fits the future-protein strategy.
Founder route: Published investment-opportunity email. Official criteria.
Compare country connections without inventing identical rules
Reimann explicitly includes all three DACH countries. ROI has an Austrian base and a European early-stage remit. Wille, Kodori, Mutschler and Armada provide different Swiss-connected routes. Halfmeyer and Stinson describe German-based company-investment strategies. These connections help identify the right question; they do not establish identical eligibility, incorporation or tax treatment.
International routes should earn their place through a relevant mandate. Adeline documents European and DACH sourcing experience. CPT publishes worldwide alternative-protein eligibility and an early entry stage. Neither should be presented as a general-purpose local investor for every DACH startup.
Who are the top family office investors?
For a startup founder, a useful shortlist is based on fit rather than family wealth. In this selection, Reimann is a specific DACH software route, Mutschler asks for early revenue, and CPT specializes in alternative proteins. The relevant investor changes when the product, development milestone or country connection changes.
Worked example: a Swiss mental-health software startup
Fictional example: a Swiss team has a working mental-health software product and initial pilot evidence. It researches Kodori because the venture arm explicitly focuses on mental health. It considers Halfmeyer only if the product is software-led and the company can use its operator approach. Mutschler becomes a different conversation once the team can demonstrate the initial revenue its criteria request.
A clinical drug company would not use that same shortlist: digital health and biotech have different evidence requirements. The founders log the source and the unknown stage question before choosing a first contact.
Copy the DACH family-capital routing worksheet
Complete a separate country and strategy check for each route, even when several investors sit in the same city.
DACH FAMILY-CAPITAL ROUTING WORKSHEET
Company and next operating milestone:
Germany connection:
Austria connection:
Switzerland connection:
Investor and actual company-investing team:
Provider type / direct-capital evidence:
Published country or regional remit:
Stage: pre-seed / seed / Series A / later / unknown
Required product or revenue evidence:
Sector exclusion or conflict:
Official source URL and checked date:
Public route / introduction needed / route unverified:
Open question, relationship owner and next action:Ask Aurora, Claude or Codex to review your shortlist
Supply your facts and the official sources. Review the result before acting; this is a research aid, not automatic outreach.
Build a DACH family-capital research queue from these company facts and official sources. Distinguish Germany, Austria and Switzerland, and separate investor offices from documented company eligibility. Classify the actual investing platform, direct-company versus fund-allocation route, entry stage, product or revenue evidence, sector exclusions and public approach route. Do not label a biotech company digital health, assume all family offices fund pre-seed, or use an old portfolio deal as current eligibility. Mark unknowns, deduplicate parents and venture arms, and return the strongest research matches with specific reasons and one next question. No legal or tax advice and no automatic outreach.Methodology and related guides
The Finta Editorial Team reviewed investor-controlled strategy, criteria, team and contact information. We count each platform once, reconcile venture arms with their parent and distinguish a stated mandate from a past deal. A current web page is not proof of remaining capital or a recent deployment. Unknown eligibility and unverified public intake are recorded openly.
Use the direct-startup family-office hub for the global capital distinction and the family-office pitch guide to prepare your introduction. Use the broader DACH venture-capital guide for institutional funds and the Austria investor guide for additional local context.
This is general research and organizational information, not personalized financial, legal or tax advice. Confirm the current investing entity, eligibility and terms directly.